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K-ras transformed fibroblasts have been shown to have a stronger dependence from glycolysis, reduced oxidative phosphorylation ability and
a fragility towards glucose depletion compared to their immortalized, normal counterparts. In this paper, using RNA profiling assays and
metabolic perturbations, we report changes in expression of genes encoding mitochondrial proteins and alterations in mitochondrial morphology
that correlate with mitochondrial functionality. In fact, unlike normal cells, transformed cells show reduced ATP content and inability to modify
mitochondria morphology upon glucose depletion. Being reverted by GEF-DN expression, such morphological and functional changes are
directly connected to Ras activation. Taken together with reported partial mitochondrial uncoupling and more sustained apoptosis of transformed
cells, our results indicate that activation of the Ras pathway strikingly impacts on energy and signaling-related aspects of mitochondria
functionality, that in turn may affect the terminal phenotype of transformed cells.
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1.1. Mitochondria and cancer
Mitochondria are dynamic eukaryotic organelles that have
long been known to play a central role in cellular metabolism,
notably in ATP production by oxidative phosphorylation [1,2].
The primary metabolic function of mitochondria is oxidative
phosphorylation (OXPHOS), an energy-generating process that
couples oxidation of respiratory substrates to the synthesis of
ATP. Mitochondria are delimited by two membranes dividing
them into two different compartments: the matrix and the inter
membrane space. The OXPHOS system comprises four redox
complexes (numbered I to IV, making up the respiratory chain),
and complex V (i.e. the ATP synthase), all located in the mito-
chondrial inner membrane. The respiratory chain transfers
electrons from NADH and FADH2, generated through the
breakdown of substrates in the matrix, or imported from the
cytosol through specific transport systems, to molecular oxygen,⁎ Corresponding author. Tel.: +39 02 64483515; fax: +39 02 64483519.
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doi:10.1016/j.bbabio.2006.08.001the terminal electron acceptor. Energy released by oxidation of
these substrates is used to generate an electro-chemical proton
gradient (ΔΨ) across the mitochondrial inner membrane. ATP
synthase couples utilization of this gradient to the synthesis of
ATP. Each complex of the respiratory chain and complex V
consist of multiple polypeptide subunits, some encoded by
nuclear genes and some encoded by mitochondrial DNA.
Protein composition, stoichiometric ratio of the various protein
subunits, post-translational modifications, tissue specificity and
the role of each and every subunit in the function of mito-
chondrial complexes are still under investigation. In mammals
the complexes I to Vare composed respectively by 42, 4, 11, 13
and 15 subunits. Respiratory chain complexes comprise core
subunits that are necessary for complex activity and other
subunits, possibly playing ancillary or modulatory roles, while
all subunits of ATP-synthase seem required for activity [1,2].
Besides ATP synthesis, mitochondria are involved in several
other key metabolic processes such as oxidative decarboxyla-
tion of pyruvate, tricarboxylic acid cycle, and fatty acid
oxidation. Mitochondria are the site of important biosynthetic
reactions, such as amino acids and heme biosynthesis and part
of gluconeogenesis. Mitochondria take part in intracellular
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as well as in the balance of NAD+/NADH, since part of NAD+,
produced by NADH oxidation in the respiratory chain, goes
back to the cytosol where it is required for glycolysis. Several
enzymes of the urea cycle are also localized in mitochondrial
matrix. Besides their central role in metabolic activity, mito-
chondria have been shown more recently to have a central role
in the cascade of events that leads to programmed cell death. In
fact, evidence has been gathered indicating a pro-apoptotic role
for several molecules usually associated to mitochondria
(cytochrome C, AIF, EndoG, Bax) as well as a role in damping
the apoptotic cascade of proteolytic enzymes (caspase) by other
molecules usually associated to mitochondria [3,4]. Thus, these
findings assign to mitochondria a more critical role in the
responses of cells to a multiplicity of physiological and genetic
stresses, inter-organelle communication, cell proliferation and
cell death [5–10].
The study of energymetabolism of transformed cells has been
a central issue of cancer research until the interest shifted to
genetic approaches. As early as 1930, Otto Warburg proposed
that cancer cells may have impaired mitochondrial function and
that this alteration would result in the elevated rate of glycolysis
that is a common feature of most tumors [11]. During the 1970s
H.A. Krebs stated that the elevated rate of glycolysis “may be a
symptom of cancer, but not a primary cause” [12–14], a concept
recently restated by Robert Weinberg who wrote that “aerobic
glycolysis is an epiphenomenon of cell transformation rather
than a casually important process” [15]. Although the glycolytic
phenotype of many cancer cells and tumors has been demon-
strated at both the biochemical andmolecular levels [16–24], the
presumed impairment of cancer mitochondrial function has
never been unambiguously established. In fact, to this day, we
still do not know the role, if any, that mitochondria play in
neoplastic transformation and/or in maintaining or promoting
the transformed state. Recent studies highlighted that mitochon-
drial dysfunction is one of the most recurrent features of cancer
cells [25–28], given that substantial differences between the
mitochondria of normal and cancer cells have been reported at
microscopic, molecular, biochemical, metabolic and genetic
level.
A fundamental role for hypoxia in emergence of mitochon-
dria dysfunction is supported from experimental and clinical
evidence. Indeed, hypoxia has been shown to alter the
expression of genes involved in stress response, anaerobic
metabolism, angiogenesis, tissue remodeling, and cell to cell
contact acting in an epigenetic and non-epigenetic fashions [29].
All these phenomena participate in the process of “adaptive res-
ponse” of cancer cells to hypoxic conditions contributing to their
growth advantage. The importance of hypoxia in tumor deve-
lopment is substantiated by several reports indicating that in
developing tumors the oxygen level declines more than glucose
level [30–33]. Cancer cells would counteract oxygen shortage
by hyperactivation of glycolysis to produce ATP. The secondary
effect of stimulated glycolysis is the accumulation of lactate in
the environment with a direct consequence on the extracellular
pH that becomes more acidic [30–33]. Cells that are able to
survive in acidic environment will be strongly advantaged,and some authors have shown, in several cancer cells, an up-
regulation of the Na+–H+ exchange and vacuolar H+-ATPase
that facilitates survival in an acidic environment [34–36].
Moreover, an acidic environment induces apoptosis in normal
neighbor cells and degradation of extracellular matrix that in turn
facilitates migration and invasion of the surrounding tissues by
well-adapted cancer cells. In this regard, it is widely recognized
that a significant number of tumors reveals over-expression of
HIF1α, which participates in the induction of some glycolytic
enzymes [8,33,37–44], of angiogenetic processes by inducing
the VEGF expression [45,46] and in the migration processes by
inducing different proteases, such as urokinase Plasminogen
Activators [47,48]. On the other hand, other authors support the
view that the metabolic shift to glycolysis directly results from
oncogenic mutations of elements of the signal transduction
pathways that control glucose uptake by the cells or of tran-
scription factors that control the expression of glycolytic and
mitochondrial genes [10,18,22,49–52]. For these reasons, the
molecular mechanisms that promote the expression of an aber-
rant energy metabolism in tumor and cancer cells are presently a
subject of renewed debate.
1.2. Alterations of mitochondria in cancer
Mitochondrial alterations specifically associated with their
bioenergetics function have been observed in cancer cells.
Mutations in mitochondrial DNA (mtDNA) are commonly
found in a variety of cancers [38,53,54]. Microscopic study of
tumors revealed mitochondrial hyperplasia, and up-regulated
expression of mitochondrial cytochrome oxidase II mRNA in
malignant breast tissues has been observed [55]. Expression
analysis in glioblastoma tissues showed reduction of cyto-
chrome C oxidase subunit II and III (COX II, COX III), ATP
synthase subunit 6 (ATP 6), NADH dehydrogenase subunit 1
and 4 (ND1 and ND4) transcripts [56].
Only recently, mitochondrial enzymes have been directly
implicated in hereditary neoplasia. Germline heterozygous
mutations in nuclear genes encoding subunits of mitochondrial
complex II (succinate-ubiquinone oxydoreductase, composed of
four subunits – SDHA, SDHB, SDHC and SDHD – and
involved in electron transport and in tricarboxylic-acid cycle)
cause inherited tumoral syndromes [46,48,57–59], while
homozygous mutations in the SDHA-encoding gene cause
neurodegenerative disorders [60,61]. Mutations in the gene
encoding fumarate hydratase (FH, fumarase that converts
fumarate to malate) cause inherited neoplastic syndromes, as
well as to kidney cancers [61,63–65], associated with a reduc-
tion in dosage of SDH or FH-encoding genes. Complete or near
complete loss of enzyme function occurs only in the somatic
tumor cells. Reduced mitochondrial SDH or FH activity might
affect apoptosis and angiogenesis induction, both hallmarks of
tumorigenesis [46,48,58,59]. In fact, defects in energy produc-
tion may block energy-dependent apoptotic processes, and up-
regulate angiogenesis, due to increased HIF1α stability resulting
from succinate inhibition of HIF1α prolyl-hydroxylase [61,62].
Further evidence of the importance of mtDNA mutations in
neoplastic transformation comes from studies of complex IV
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cytochrome c oxidase activity in total cellular homogenate and
in mitochondrial samples from cultured human carcinoma cell
lines has been shown to be significantly lower than that mea-
sured in the control epithelial cell line [25].
Specific repression of the expression of the β-catalytic
subunit of the H+-ATP synthase (β-F1-ATPase), a rate-limiting
component of mitochondrial oxidative phosphorylation, has
been documented in rat hepatocarcinomas, in several human
tumors[67], and notably of carcinomas [68,69]. Decreased
expression of β-F1-ATPase observed in the inner core of some
carcinomas is accompanied by concurrent up-regulation of
glycolytic enzymes in most of the human solid tumors ana-
lyzed and might result from a partial hypoxic environment in
such tumors. Reduced adenine nucleotide translocase activity
has been reported in certain hepatoma versus normal liver
mitochondria [70,71] and it has been correlated to the aggres-
siveness of cancer cells [72]. Evidence has been collected
indicating that pathogenic mtDNA mutations that impinge on
mitochondrial energy transduction do play a relevant role in
the etiology of cancer by any of the following mechanisms:
excessive reactive oxygen species production, reduced cellular
apoptotic potential or altered mitochondria to nucleus signaling
in a cellular invasive phenotype [54,73], suggesting that altered
glycolysis of cancer cells could be a consequence of
mitochondrial dysfunction.
1.3. A fibroblast model for the study of mouse mitochondrial
function in transformed cells
As briefly summarized above, mitochondria are involved
in different, interacting intracellular networks in both normal
and transformed cells. If one wants to identify the network(s)
that presides and regulates the process under investigation
[74], it is necessary to start by analyzing the network(s) under
study using a defined, genetically tractable model both for
normal and transformed cells in which the transformed phe-
notype can be switched on and off by defined molecular
events.
We have developed an experimental system comprising
normal, K-ras transformed and reverted, isogenic cell lines using
NIH3T3 fibroblasts. The use of NIH3T3 cells to assay theFig. 1. Comparative analysis of Ras- and GEF-DN- regulated genes using Affymetr
plated at 3000 cell/cm2 in media supplemented with 25 mM glucose and used for th
identified by using Affymetrix MG_U74Av2Array as described in Materials and met
change ≥1 in each of the two independent experiments is reported in the table. (B
differentially regulated in at least one pair-wise comparison. Fold changes are calcul
pathway whose regulation was scored not change (NC) in the Affymetrix arrays. R
dehydrogenase complex, subunit C, cytochrome c oxidase; subunit Va, cytochrom
cytochrome c oxidase, subunit VIIa 1; cytochrome c oxidase subunit VIIa polypep
VIIc; cytochrome c oxidase, subunit VIIIa; ATP synthase, F0 complex subunit F;
polypeptide 2; ATP synthase, F1 complex, O subunit; NADH dehydrogenase (ubi
subcomplex 2; NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4; NADH
(ubiquinone) 1 alpha subcomplex 7; NADH dehydrogenase (ubiquinone) 1 beta su
dehydrogenase (ubiquinone) 1, subcomplex 1; NADH dehydrogenase (ubiquinone)
dehydrogenase flavoprotein 1; NADH dehydrogenase (ubiquinone) flavoprotein 2. (C
primers as indicated in Materials and methods, using samples from normal (lane N), t
The vinculin transcript was used as endogenous controls for semiquantitative RT-PCtransforming ability of potential and known oncogenes is well
documented. Developed by Tordaro and Green [75] as a cell line
for transformation studies, this mouse fibroblastic cell line is
largely employed for its indefinite growth in culture, retention of
contact inhibition, and ease of transformation due to mutations
or expression of introduced genes. The ability of transformed
3T3 to overcome contact inhibition when plated in soft agar is a
powerful tool, used to examine the oncogenic potentialities of
genes such as Ras [76], sphingosine kinase [77] and the G-
protein linked T151M mutant calcium sensing receptor (CaR)
[78]. Moreover several reports found coherent correlation be-
tween the results obtained in this cellular model with findings in
tumor tissues and animal models [79–82].
Ras proteins are intracellular switches whose activation state
(i.e. their binding to GDP and GTP) controls downstream
pathways leading to cell growth and differentiation. The
activation state of Ras proteins is governed through the
competing action of GTPase Activating Proteins (GAP) and
Guanine nucleotide Exchange Factors (GEF). Mutation of the
ras gene is a critical event in the onset of different malignant
phenotypes. Also deregulation of either GAP or GEF activity
may result in hypo- or hyper-activation of downstream pathway
(s), so that for instance over-expression of a GEF or inactivation
a GAP may both result in cell transformation [83–85].
Research performed in our laboratory indicates that a single
amino acid change within the catalytic domain of the
mammalian GEF CDC25Mm turns this molecule into a dominant
negative protein (called GEF-DN). GEF-DN is able to efficiently
displace wild-type GEF from p21ras and to originate a stable
Ras–GEF binary complex due to the reduced affinity of the
nucleotide-free Ras–GEF complex for the incoming nucleotide
[86]. This “Ras-sequestering property” can be utilized to
attenuate Ras signal transduction pathways in mouse fibroblasts
transformed by oncogenic ras, since GEF-DN expression down-
regulates Ras activity both in vitro and in vivo and induces a
reversion of the transformed phenotype on the basis of
morphology, anchorage independent growth and reduction of
Ras-dependent tumor formation in nude mice [87]. Thus, the use
of three cell lines: normal NIH3T3 mouse fibroblasts (that we
refer to as normal, or N); NIH3T3 cells transformed by an
activated form of the K-ras oncogene [88,89] (that we refer to as
transformed, or T) and K-ras transformed NIH3T3 fibroblastsix arrays. (A) The normal (N), transformed (T) and reverted (R) cell lines were
e RNA extraction after 48 h of growth. The differentially expressed genes were
hods. The number of genes showing differentially expression with at least a fold
) The Table shows some mitochondrial proteins whose mRNA expression was
ated as 2SLR (Signal Log Ratio). Below are listed the genes considered for each
espiratory Chain (NC) succinate dehydrogenase complex, subunit B; succinate
e c oxidase subunit Vb; cytochrome c oxidase subunit VI a, polypeptide 1;
tide 2-like; cytochrome c oxidase subunit VIIb; cytochrome c oxidase, subunit
ATP synthase, F0 complex, subunit c; ATP synthase, F0 complex, subunit f,
quinone) 1 alpha subcomplex 1; NADH dehydrogenase (ubiquinone) 1 alpha
dehydrogenase (ubiquinone) 1 alpha subcomplex 6; NADH dehydrogenase
bcomplex 5; NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9; NADH
Fe–S protein 3; NADH dehydrogenase (ubiquinone) Fe–S protein 4; NADH
) Validation of selected genes by RT-PCR. RT-PCR was conducted with specific
ransformed (lane T) and reverted (lane R) cell lines cultured as described above.
R.
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or R [87]) allows us to directly assess the role played by the Ras
activation in the any given studied phenotype.In this paper, using an RNA profiling assay and metabolic
perturbations, we report changes in expression of genes
encoding mitochondrial proteins and alteration in mitochondrial
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fact transformed cells show a reduction of ATP cellular content
in correlation to glucose depletion and inability to modify the
mitochondria morphology as normal cell does. Such morpho-
logical and functional changes are directly connected to Ras
activation, since they are reverted by GEF-DN expression.
Together with the reported partial uncoupling and larger fraction
of apoptotic cells in the transformed line, our results indicate
that activation of the Ras pathway strikingly impacts on
energetic and signaling-related aspects of mitochondria func-
tionality that in turn may affect the terminal phenotype of the
transformed cell.
2. Materials and methods
2.1. Cell culture
Normal mouse fibroblasts (obtained from the ATCC, Manassas, VA, USA)
and a K-Ras-transformed normal-derived cell line, 226.4.1 [90], were routinely
grown in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA,
USA) containing 10% newborn calf serum, 4 mM glutamax, 100 U/ml penicillin
and 100 mg/ml streptomycin (normal growth medium), at 37 °C in a humidified
atmosphere of 5% CO2. The reverted cell line, stably and constitutively
expressing the dominant mutant Cdc25W1056E (GEF-DN) [87] was maintained
in normal growth medium supplemented with 0.7 mg/ml geneticin (G418;
Sigma-Aldrich Inc., St. Louis, MO, USA). Cells were passaged using trypsin-
ethylenediaminetetraacetic acid (EDTA) (Invitrogen) and maintained in culture
for 48 h before experimental manipulation. To verify the cell response to the
glucose depletion, the cells were grown in medium with 4 mM glutamax and
without glucose and sodium pyruvate (Invitrogen) supplemented with the
appropriate concentration of glucose (25 and 1 mM).
2.2. RNA preparation and Affymetrix Analysis
For the Affymetrix Gene Chip screening the three cell lines were plated
3000 cells/cm2 in high glucose (25 mM). After 2 days the cells were detached
to prepare the mRNAs and the relative cRNAs. Total RNAwas prepared using
Trizol reagent (GIBCO-BRL, Grand Island, NY, USA), following the manu-
facturer's protocol. Double-strand cDNA was synthesized from total RNA
using Superscript™ cDNA Synthesis kit (Life Technologies, Carlsbad, CA,
USA) and the oligo T-7-(dT)24 primer that contained a T-7 RNA polymerase
site. cDNA was in vitro transcribed using the T7 BioArray High Yield RNA
Transcript Labeling Kit (Enzo Biochem, Farming Dale, NY, USA) to produce
biotinylated cRNA. Labeled cRNA was isolated using an RNeasy Mini Kit
column (Qiagen Inc., Valencia, CA, USA). Purified cRNA was fragmented to
200–300 mer cRNA using a fragmentation buffer as suggested by Affymetrix
protocol. Housekeeping controls α-actin and GAPDH genes served as endo-
genous markers and were added to the sample to monitor the quality of the
target.
Biotin-labeled cRNAs were hybridized to anMG_U74Av2 Affymetrix Gene
Chip. Hybridization experiments were repeated twice using independent cRNA
probes synthesized with RNA from two independent sets of cells. Data presented
in this work represent the average of both experiments.
Raw data were analyzed using Affymetrix Gene Chip software Mass 5.1.
Fold change was calculated using the Affymetrix Gene Chip software with a
Comparison Analysis where two samples, hybridized to two Gene Chip probe
arrays of the same type, are compared with different types of algorithm against
each other in order to detect and quantify changes in gene expression. Results
were further elaborated through replica and statistical methods using various
software.
2.3. Semiquantitative reverse-transcription-PCR
RNAwas extracted from cells cultured as described above. Total RNAwas
incubated with DNase I RNase-Free (Abgene, New York, USA) at 37 °C for 1 h.The RNA was quantified measuring the absorbance at 260 and 280 nm in a
spectrometer Lambda EZ 201 (PerkinElmer) and then stored at −80 °C.
Five micrograms of total RNA were reverse-transcribed with oligo dT by
using the Superscript™ III RT-PCR First-Strand Synthesis System for RT-PCR
(Invitrogen Corp., Carlsbad, CA, USA).
One microliter of the RT product was amplified with primer pairs specific for
the genes studied. Specifically for UCP-3: forward ATGAGTTTTGCC-
TCCATTCG reverse AAGGAGGGCACAAATCCTTT; TFAM: forward
TAGGAAAATTGCAGCCCTGT reverse CTTCAGCCATCTGCTCTTCC;
TOMM40: forward TCCAGGTGACCCACACAGTA reverse CCAGCTGA-
TACCCAAAGGAG; TST: forward CCCACTTTGGGGACTATGTG reverse
TTCTCGAAGCCATCTTTCGT; COX6c: forward CACAGATGCGTG-
GTCTTCTG reverse CATAGTTCAGGAGCGCAGGT; COXI: forward GCA-
ACCCTACACGGAGGTAA reverse AGGTTGGTTCCTCGAATGTG; COXII:
forward TCTCCCCTCTCTACGCATTC reverse TCAGAGCATTGGCCATA-
GAA; COXIII: forward AGGCCACCACACTCCTATTG reverse TGGAATC-
CAGTAGCCATGAA. As internal control of PCR assays were designed specific
primers for vinculine transcript VCL: forward GGGTTTGCAAAGGAATT-
TTGG reverse CAGGAAGCAGCTCTTTGACA. The reaction mixture of 30 μl
contained 1/30 volume of cDNA, 200 nM of each dNTP, 1 unit of REDAccuTaq
DNA Polymerase (Sigma-Aldrich S.r.l. Milan, Italy), 10× buffer (supplied with
enzyme), and 0.5 μM each of the forward and reverse primers. The mixture was
subjected to amplification using an Eppendorf Mastercycler (Eppendorf,
Hamburg, Germany). The reaction with each couple of primers was performed
with an initial denaturation at 95 °C for 2 min, followed by 20–30 cycles of
denaturation at 95 °C for 30 s (different cycles were used to avoid a saturating
amplification), annealing at 56 °C for 1 min, and extension at 72 °C for 1 min. A
final 5 min extension step was added after the last cycle. Fifteen μl of RT-PCR
product were loaded on 1.5% agarose gel and visualized by ethidium bromide
staining and photographed under UV light.
2.4. Digital imaging microscopy for mitochondrial morphology in
living cells
For the visualization of mitochondrial morphology in living cells we used
normal, transformed and reverted cells cultured in high and low glucose (1 mM)
and attached on cover glasses treated with 0.2% gelatin. To visualize the
mitochondria MitoTracker Green FM (200 nM) and CMXRos (MitoTracker
Red) (60 nM) (Molecular Probes Inc., Eugene, OR, USA) were used, adding the
dyes directly in the culture medium for 39′ at 37 °C. Then the cover glasses were
washed twice with PBS and directly analyzed under a Nikon ECLIPSE 90i
fluorescence microscope equipped with a b/w CCD camera (Hamamatsu-
CoolSnap, Hamamatsu Corporation, Japan), using Plan Apo objective (60× oil;
numerical aperture 1.4) and Plan Fluor objective (100×; numerical aperture 1.3).
Analysis of the images was also performed using Z-stacks images acquired on a
motorized Nikon ECLIPSE 90i (Nikon Corporation, Tokyo, Japan). The images
were deconvolved using the iterative algorithm in MetaMorph 7 and evaluated
as best focus intensity projections.
2.5. Mitochondrial mass and potential analysis in living cells
Mitochondrial mass and potential were determined with the probes
MitoTracker Green (60 nM) and CMXRos (MitoTracker Red) (60 nM)
(Molecular Probes) using fluorescence-activated cell sorter (FACScan, Becton-
Dickinson). Briefly, cells were trypsinized by treatment with 0.25% trypsin, then
were suspended in 1 ml of PBS+10% FCS (0.5×106 cells per analysis)
containing the two dyes separately at the above indicated final concentrations
and labeled for 30 min at 37 °C in the dark. Subsequently cells were washed
once in PBS+10% FCS and promptly used for flow cytometric analysis. In
some experiments, the cells were pretreated for 10 min with 50 μM carbonyl
cyanide 3-chlorophenylhydrazone (CCCP, Sigma-Aldrich S.r.l. Milan, Italy)
and stains added to the CCCP containing solution for an additional 30 min at
37 °C. The unbound dyes were then removed with one wash, as above, and
promptly used for flow cytometric analysis. The percentage and the mean value
of mass and potential were calculated for each sample and corrected for auto-
fluorescence obtained from samples of unlabeled cells. Data analysis was
performed with WinMDI software.
1343F. Chiaradonna et al. / Biochimica et Biophysica Acta 1757 (2006) 1338–13562.6. ATP and ADP quantification
Intracellular ATP and ADP contents were determined based luciferin/
luciferase method with use of ApoSensor ATP-ADP ratio bioluminescent assay
kit (Eppendorf, Hamburg, Germany), following the manufacturer's instructions.
Briefly, the cells supplemented with high or low glucose, were washed with
PBS, detached from plates by using trypsin/EDTA solution and then counted.
For each assay 10,000 cells/sample were used, and each experiment was
performed in duplicate. The RLU values recorded by Lumat LB9507
luminometer (Berthold Technologies, Bad Wildbad, Germany) were normalized
by protein concentration determined for each sample by the method of Bradford
using Bio-Rad protein assay (Bio-Rad Laboratories, Milan, Italy).3. Results
3.1. Transcriptional profiling of genes encoding mitochondrial
proteins in normal, transformed and reverted mouse fibroblasts
Transcriptional profiling of normal, transformed and
reverted mouse fibroblasts has been reported [10]. Here we
extend such an analysis to expression of genes encoding
mitochondrial proteins, taking in consideration for this
purpose also genes whose regulation was scored as one fold
change in two independent experiments. Microarray analysis
was validated by RT-PCR on 5-regulated transcripts, using
vinculin as a non-changing control. RNA profiling and RT-
PCR results for the selected RNAs showed strong correlation
(Fig. 1C).
As shown in Fig. 1A, around 6% of total genes scored as
regulated in transformed cells vs. normal cells (with a fold
change ≥1 or ≤−1) are mitochondrial genes. Moreover, if we
extend this estimation adding the results of the transcriptional
analysis reported in our previous paper [10], we observe that
around 10% of total regulated genes (with a fold change ≥1
or ≤−1) in the comparison between transformed cells vs.
normal cells, are linked to energy-production pathways,
indicating that oncogenic k-ras induces a strong remodeling
of metabolism during the transformation process. Detailed
analysis of these genes encoding mitochondrial proteins (Fig.
1B) showed that several genes encoding subunits of
cytochrome oxidase were either up- or down-regulated in
transformed vs. normal cells. RNA levels of the mitochondrial
encoded COX proteins (I, II and III), that are not present onto
the Affymetrix chip, were tested by RT-PCR. The level of
these RNAs was not affected in k-ras-transformed cells (Fig.
1C), suggesting that assembly of the COX complex may be
impaired in the transformed cell line. Interestingly, trans-
formed cells showed up-regulation of the cytochrome c
oxidase assembly protein COX 17, a key mitochondrial
copper chaperone involved in the assembly of cytochrome c
oxidase, which has been found to be over-expressed in non-
small cell lung cancer [91]. Expression of several genes
encoding subunits of ATP synthase (F1F0, an oligomer of
about 14 polypeptides that are all essential for its catalytic
activity) was also altered in transformed cells.
Cellular control over adaptive changes in mitochondrial
content requires ability to sense the requirement for additional
mitochondrial energy production, followed by triggering ofsignaling pathways that culminate in an increased and
coordinated expression of “respiratory” genes and ensuing up-
regulation of mitochondrial function. These processes are
controlled by different transcription factors and it was
interesting to find some important regulators of mitochondrial
biogenesis, integrity and functionality differentially expressed
in transformed cells. As shown in Fig. 1B, mitochondrial
transcription factor A (TFAM), essential for the maintenance of
mtDNA [92], was up-regulated in transformed cells. In the same
cells, another well-characterized example of regulation of
metabolic pathways, the transcriptional coactivator peroxisome
proliferator-activated receptor gamma coactivator-1α (PGC-1α)
[93], appeared to be down-regulated. PGC-1α activates gene
expression through specific interaction with transcription
factors that bind the promoters of genes encoding metabolic
enzymes. Two tissue-specific factors as the muscle enhancer
factor (MEF2A) and hepatocyte nuclear factor (HNF4) were
found down-regulated. Other transcription factors, such as the
nuclear factors erythroid-related and -derived Nrf1 and Nfe2l3,
involved in the activation of transcription of a series of genes
induced in defensive response to antioxidants were also found
to be down-regulated.
Developing mitochondria acquire most of their proteins by
the uptake of mitochondrial preproteins from the cytosol [1]. To
mediate this protein import, both mitochondrial membranes
contain independent protein transport systems: the Tom
machinery in the outer membrane and the Tim machinery in
the inner membrane. Both TOM40 and syntaxin 2, necessary
proteins for the transport process were found to be up-regulated
in transformed cells [94–96]. Tim44, which serves as an adaptor
protein for the binding of mtHsp70 to the membrane, that
participates to the processing of preprotein after cleavage of the
presequence [97,98], also was found to be down-regulated in
transformed cells. Another protein that has been found down-
regulated in transformed cells was Uncoupling protein 3
(UCP3). UCP3 belongs to a protein family that comprises
UCP1, 2 and 3. These proteins are involved in several mito-
chondrial processes and in different human pathologies
[65,99,100]. We found other mitochondrial genes, indicated as
various processes in Fig. 1B, both up- and down-regulated in
transformed cells.
These k-ras-induced effects are substantially reverted by
GEF-DN expression (Fig. 1B compare column T/R with R/T),
since they take place under normoxic conditions, they are not an
adaptive response of transformed cells to oxygen limitation.
3.2. Alterations in mitochondria morphology of transformed
cells is reverted by expression of the GEF-DN
The penetrance of the transformed phenotype in mouse 3T3
fibroblasts stably transfected with the k-ras oncogene is
dependent on glucose availability [10]. Thus, normal, trans-
formed and reverted fibroblasts were grown in media supple-
mented with either normal (25 mM) or low (1 mM) initial
glucose concentration. Cells were followed for at least 96 h, i.e.
from the moment of seeding to when they either reached con-
fluence or started to grow in multi strata or to die. Experiments
Fig. 2. Mitochondrial morphology of normal, transformed and reverted cell lines in high glucose availability.Mitochondrial staining of normal (N; A andD), transformed (T; B
and E) and reverted (R; C and F) cells withMitoTracker Green FM, using two different objectives (60× and 100×) andmagnified view of corresponding boxed area in the right
panels. The cells for microscopic analysis were grown for 24 h (1) and 96 h (2) in 25 mM glucose. The pictures are representative of several observations on living cells.
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mentioned experimental set-up.
In a first set of experiments we analyzed mitochondria
morphology by fluorescence microscopy of cells stained with
MitoTracker Green FM, a dye that becomes fluorescent once it
accumulates in the lipid environment of mitochondria. As
shown in Fig. 2(1), panels A, C, D, F and magnifications,
mitochondria of normal and reverted cells, after 24 h of growth
in medium supplemented with 25 mM initial glucose
concentration, appeared fragmented, with short and long rods
partially clustered in the perinuclear region. The same analysis
performed on transformed cells showed a more fragmented
mitochondrial configuration, less organized structures and no
clustering in the perinuclear region (Fig. 2(1), panels B, E and
magnification). The differences in mitochondrial structures
were analyzed also at 96 h after plating in the same initial
glucose concentration, time at which normal and reverted cells
showed an increased G1 fraction due to contact inhibition, while
transformed cells continued to grow [10]. Compared to the
earlier time point, normal and reverted cells showed a more
interconnected mitochondrial network and a decreased peri-
nuclear clustering (Fig. 2(2) panels A, C, D, F and magnifica-
tions), while transformed cells (Fig. 2(2) panels B, E and
magnification) showed mitochondrial fragmentation and
appearance of a larger number of cytoplasmatic, diffuse small
mitochondrial spheres, structures that could be related to the
beginning of apoptotic process, observed at low but consistent
frequency at this time point only in transformed cells (ref. [10]
and data not shown).
Mitochondria of normal cells grown for 24 h in medium
supplemented with 1 mM initial glucose concentration were
more fragmented and less clustered in the perinuclear region
than the same cells after 24 h of growth in medium
supplemented with 25 mM initial glucose concentration
(compare panel A, D and magnification in Figs. 3((1) and 2
(1)). Reverted cells were highly similar to normal cells with
more evident cytoplasmic redistribution and decreased peri-
nuclear localization (Fig. 3(1), panel C, F and magnification).
On the contrary, no significant redistribution of mitochondria
was observed in transformed cells, whose staining pattern was
very similar to that of cells grown in 25 mM glucose (compare
panel B, E and magnification in Figs. 3((1) and 2(1)). After
96 h of growth in medium supplemented with 1 mM initial
glucose concentration, the mitochondrial reticulum of normal
cells appeared more extended in long thinner processes
different from the pattern observed in cells grown in 25 mM
glucose at the same time point (compare Panels A, D and
magnification in Figs. 3(3(2) and 2(2)). A similar morphology
was observed in reverted cells, except that the mitochondrial
elongations appeared thicker than in normal cells (Fig. 3(2),
panels C, F and magnification). Transformed cells showed
mitochondrial fragmentation similar to the one observed in
high glucose condition (Fig. 3(2), panels B, E and magnifica-
tion). In low glucose conditions, transformed cells showed a
notable increase of apoptosis, while normal and reverted cells
strongly accumulate in G1 phase of cell cycle ([10] and data
not shown).3.3. Alteration in mitochondrial mass and potential of
transformed cells is reverted by expression of the GEF-DN
Cells grown as described in the previous section were
analyzed for the distribution of mitochondrial mass and
potential by flow cytometry. Cells were independently stained
with MitoTracker Green FM, (see previous chapter) whose
fluorescence monitors total mitochondrial mass and Mito-
Tracker Red, a dye whose fluorescence is dependent on
mitochondrial potential (ΔΨ). Specificity of MitoTracker Red
has been first verified by flow cytometry. Fig. 4A, B and C
shows the fluorescence level obtained by flow cytometry – with
or without treatment with 50 μM CCCP, a mitochondrial
depolarizer – in normal, transformed and reverted cells (panels
A, B, C, respectively). After detachment from the plates, each
cell line was treated for 10 min with 50 μM CCCP and then
labeled with the MitoTracker Red for additionally 30 min, to
analyze the mitochondrial potential. As shown in the Fig. 4A, B
and C the three cell lines showed a strong reduction of potential
after the treatment with CCCP (compare in the three panels the
red curves with blue curves) indicating the specificity of the dye
for mitochondrial potential. Specificity of MitoTracker Red, as
well as of MitoTracker Green was further evaluated by
microscopy. As shown in Fig. 4 when the cells treated with
(Fig. 4D, E and F) or without (Fig. 4G, H and I) CCCP were
loaded with both MitoTracker Red (MTR) and MitoTracker
Green FM (MTG) and then imaged, they showed only a
reduction in red staining (MTR) but not of green staining
(MTG). In fact the outcome of merging the pictures obtained by
the two dyes gave as results a yellow staining in absence of the
uncoupler agent CCCP (Fig. 4G, H and I) and only a green
staining in presence of the same agent (Fig. 4D, E and F),
indicating a reduction of mitochondrial potential and a minor
effect, if any, on mitochondrial mass (MTG staining), as we
already observed using CCCP and MTG staining by flow
cytometry (data not shown).
Data for mitochondrial mass are reported in Fig. 5 and data
for mitochondrial potential in Fig. 6. In both Figures, the three
upper panels report auto fluorescence for normal (panel A),
transformed (Panel B) and reverted (Panel C) cells. These
panels were used to calibrate analysis (i.e. to score unstained
cells) in panels reported below. As shown in Fig. 5, panels D
through I, proliferating cells grown for 24 h in media
supplemented with 25 and 1 mM initial glucose concentrations,
showed similar percentage of stained cells (right values on the
panels: LR) and not stained (left values on the panels: LL). In
both media, the LL values sharply decreased as a function of
time for both normal and reverted cells, reaching a minimum
after 96 h of growth. On the contrary, transformed cells
consistently showed a peak of LL value at 72 h. Such a value
decreased at the later time point, but still remained higher than
in normal and reverted cells. In all cell lines, the value of Mean
Fluorescence (MF) remained about constant after 24 and 72 h of
growth, but sharply increased at the last examined time point,
i.e. 96 h. At this time point normal cells showed two distinct
subpopulations (panels R and U). The subpopulation with high
fluorescence is very limited in transformed cells grown in
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Fig. 4. Effect of uncoupling agent CCCP on staining of mitochondria with MitoTracker Red and MitoTracker Green FM. The three cell lines, normal (N),
transformed (T) and reverted (R), were treated for 10 min with 50 μM CCCP followed by labeling for 30 min with 60 nM MitoTracker Red and then analyzed by
flow cytometry (A, B and C), or labeled with 60 nM MitoTracker Red and 200 nM MitoTracker Green FM after a treatment (D, E and F) or not (G, H and I) with 50
μM CCCP and then analyzed by fluorescence microscopy. The results of the merge of the two pictures acquired for both dyes in the same field are shown in the 6
bottom panels of microscopic analysis.
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value as compared to normal cells. Reverted cells showed on
intermediate condition (panel T).
Growth in media supplemented with 1 mM initial glucose
concentration gave a similar pattern for MF, but while the
maximum MF reached by normal and reverted cells was lower
than in 25mMglucose, the maximalMF reached by transformed
cells was the same as for the cells grown in 25 mM, so that in this
condition transformed cells displayed the highest mitochondrial
mass. Interestingly at this time point, two distinct subpopula-
tions were readily apparent also in transformed cells.
Parallel samples were analyzed for mitochondrial ΔΨ by
staining with MitoTracker Red (Fig. 6). Staining pattern was
quite similar to that observed for MitoTracker Green FM
staining, i.e. the fraction of unstained cells (LL) decreased with
time in both normal and reverted cells, while it remained high in
transformed cells. MF steadily increased with time in all cell
lines. As observed with MitoTracker Green staining, the MF
value was higher for normal and reverted cells grown in 25 mM
glucose concentration, while transformed cells displayed the
higher MF value after growth in media supplemented with
1 mM initial glucose concentration. Little, if any, evidence for
two sub-populations within stained cells was apparent.Fig. 3. Mitochondrial morphology of normal, transformed and reverted cell lines
transformed (T; B and E) and reverted (R; C and F) cells with MitoTracker Gree
corresponding boxed area in the right panels. The cells for microscopic analysis were
of several observations on living cells.3.4. Effect of glucose availability on cellular ATP therein
normal, transformed and reverted cell lines
Glucose is the main substrate for intracellular ATP genera-
tion. We have previously shown that the transformed cell line
has a high rate of glycolysis, necessary to sustain its enhanced
proliferative capacity, accompanied by a larger production of
lactate and a partial uncoupling of mitochondrial respiration
chain [10]. The result of the analysis of mitochondrial potential
(ΔΨ), mitochondria propriety strongly associated with the
capacity to generate ATP, performed on the cells grown in high
and low glucose availability, showed an increasing potential
along the time-course and little differences between the three
cell lines. Therefore we decided to evaluate the intracellular
ATP content in cells grown in high and low glucose availability.
When the measurement of ATP levels was performed in active
proliferating cells (24 h in 25 and 1 mM glucose) the three cell
lines showed similar ATP levels (Fig. 7A and B) and a low
ADP/ATP ratio (Fig. 7C and D). After 96 h of growth in high
glucose medium (25 mM) the amount of ATP contained in the
three cell lines decreased by 35%, 32% and 28% respectively
for normal, transformed and reverted cells when compared to
values obtained at 24 h (Fig. 7A and B), resulting in a slightin low glucose availability. Mitochondrial staining of normal (N; A and D),
n FM, using two different objectives (60× and 100×) and magnified view of
grown for 24 h (1) and 96 h (2) in 1 mM glucose. The pictures are representative
Fig. 5. Effect of oncogenic K-Ras and glucose availability on themitochondrial mass of proliferating and arrested cells. Normal, transformed and reverted cells, cultured
in 25 mM glucose for 24 h (D-F, exponentially growing cells), 72 h (L-N) and 96 h (R-T, G1 arrested cells) and in 1 mM glucose, at the same time points, 24 h (G-H,
exponentially growing cells), 72 h (O-Q) and 96 h (U-W, G1 arrested cells), were analyzed by FACS after MitoTracker Green FM staining. (A) Normal, (B) transformed
and (C) reverted, panels were used as controls of cell auto fluorescence. Indicated in each panel are the percentage of positive stained population – LowRight - (LR), the
not stained population – Low Left - (LL) and the mean fluorescence of stained population – Mean Fluorescence - (MF). The panels are representative of at least 3
experiments.
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Fig. 6. Effect of oncogenic K-ras and glucose deprivation on the mitochondrial potential (ΔΨ). Normal, transformed and reverted cells, cultured in 25 mM glucose for
24 h (D-F, exponentially growing cells), 72 h (L-N) and 96 h (R-T, G1 arrested cells) and in 1 mM glucose, at the same time points, 24 h (G-H, exponentially growing
cells), 72 h (O-Q) and 96 h (U-W, G1 arrested cells), were analyzed by FACS after MitoTracker Red staining. (A) Normal, (B) transformed and (C) reverted panels
were used as controls of cells auto fluorescence. Indicated in each panel are the percentage of positive stained population – Low Right - (LR), the not stained
population – Low Left - (LL) and the mean fluorescence of stained population – Mean Fluorescence - (MF). The panels are representative of at least 3 experiments.
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Fig. 7. ATP production and [ADP]/[ATP] ratio of normal, transformed and reverted cells in high and low glucose availability. ATP and ADP content were measured
using a luciferin-luciferase assay in the three cell lines along the time course in high (A and C) and low glucose availability (B and D). The results were calculated in
RLU (relative light unit) after normalization for protein content of each sample.
1350 F. Chiaradonna et al. / Biochimica et Biophysica Acta 1757 (2006) 1338–1356increase of the ADP/ATP ratio (Fig. 7C and D). In normal cells,
the drop in ATP level after 96 h of growth in low glucose
medium was the same observed in high glucose media (36%).
Strikingly, ATP level dropped significantly (77%) in trans-
formed cells at the same time point, while an intermediate drop
(55%) was observed in reverted cells (Fig. 7B). As a result, the
ADP/ATP ratio in transformed cells increased dramatically as
compared to normal and reverted cell lines (Fig. 7D).
4. Discussion
Increasing evidence accumulated in recent years, confirms
previous observations indicating that energy metabolism of
cancer cells and tumors significantly differs from that of normal
cells and healthy tissues. Tumor cells have been showed to have a
higher glycolytic rate attributed to mitochondrial dysfunction
and/or hypoxic environment of developing tumor, a condition
that would force cancer cells to use essentially glycolysis to
generate ATP. Mitochondrial dysfunctions have been shown to
be due in part to mtDNA mutation and/or aberrant expression
of metabolic and mitochondrial enzymes, while hypoxia is due
to low vascularization that limits oxygen supply in growing
tumors.
4.1. Ras activation and mitochondrial dysfunction
While the relation between oncogenes and tumor suppressors
with onset of tumor phenotype has been well dissected in terms
of deregulation of some fundamental cellular processes as cell
cycle, survival, apoptosis and migration, less is known about theinfluence of oncogenes on energy metabolism of tumors. A
correlation between Myc activation and p53 inactivation and
altered expression of genes encoding glycolytic and mitochon-
drial proteins has been reported [20,22,101–107]. Correlations
between oncogenic Ras and energy metabolism have also been
reported [51]. A fully transformed state, obtained by combined
expression of different transforming proteins (telomerase, large
and small T antigen and H-Ras) showed a correlation between
tumor aggressiveness, dependence on glycolytic energy produc-
tion and decreased dependence on mitochondrial energy
production [23]. Inhibition of Ras using the Ras inhibitor
trans-farnesylthiosalicylic acid (FTS) or Ras antisense showed
down-regulation of HIF-1α, glycolysis and ATP with a conse-
quent increased apoptosis [108] or up-regulation of mitochon-
drial enzymes [109]. The relation between Ras pathways and
biogenesis and activity of mitochondria has been more
thoroughly investigated in yeast, where it has been shown that
Ras proteins transmit information on nutritional state to mito-
chondria by regulating expression and activity of mitochondrial
proteins [39,110–112].
Here we make use of a model of immortalized mouse
fibroblasts and isogenic k-ras transformed and GEF-DN re-
verted cells (see Introduction and refs. [10] and [87]), to directly
correlate oncogenic ras activation with mitochondrial (dys)
function. Results obtained here and elsewhere [10] by a combi-
nation of techniques are summarized in Fig. 8. Color-coding
refers to transcriptional regulation in transformed vs. normal
cells as follows: red, up-regulation; green, down-regulation;
yellow, no change. Cyan-colored proteins indicate that no RNA
was detected by RNA profiling assays.
Fig. 8. Metabolic rerouting in transformed mouse fibroblasts by expression of oncogenic K Ras. In transformed cells the expression of oncogenic K-Ras protein
induces a higher rate of glycolysis (red arrow), resulting in accumulation of lactic acid in culture medium, a reduction of fatty acid biosynthesis (green arrow) and a
partial uncoupling of mitochondria. These phenomena are substantiated by a transcriptional remodeling of several genes that regulate different pathways (i.e.
glycolysis, mitochondrial respiration and cell cycle) most likely necessary to adapt the metabolism of transformed cells to proliferate and survive in normoxic and
hypoxic environment, conditions observed in early and late steps of developing tumors. Transcriptional profiling of normal and transformed cells showed that several
genes encoding mitochondrial proteins are either up-regulated (subunits colored in red) or down-regulated (subunits colored in green) in transformed cells as compared
to normal or reverted cells. Genes whose expression did not change in transformed cells are shown in yellow, while genes not identified in the Affymetrix screen are
shown in cyan. This transcriptional remodeling influences the morphology and the capacity to adapt the mitochondria to variation in substrate availability (bottom part
of picture). In fact while normal cells increase mitochondrial mass and mitochondrial interconnections (Bottom B and C), probably to facilitate optimal use of the
available substrate, transformed cells that essentially rely on glycolysis, are able to proliferate until glucose is available (Bottom B) because in low glucose (Bottom C),
despite their increase in mitochondrial potential, they go in apoptosis probably due to uncoupled mitochondria (Bottom A) and fragmented mitochondria,
characteristics often observed in apoptotic cells or in non-functional mitochondria. GEF-DN expression reverts the transformed phenotype to one very close to the
normal cells. Direct interaction with Ras is shown by heavy black line while “global” phenotypic effects are indicate by thin line (see the bottom part of the figure).
1351F. Chiaradonna et al. / Biochimica et Biophysica Acta 1757 (2006) 1338–1356
1352 F. Chiaradonna et al. / Biochimica et Biophysica Acta 1757 (2006) 1338–1356An increased glycolytic flux, down-regulated expression of
several genes involved in fatty acid biosynthesis, unbalanced
transcription of genes encoding subunits of the pyruvate
dehydrogenase complex, subunits of respiratory complex II
and IV as well as of ATP synthase was observed in ras-
transformed fibroblasts vs. their normal and reverted counter-
parts (Figs. 1 and 8 and ref. [10]). Altered transcription of genes
encoding subunits of complexes IV and ATP synthase has been
associated with regulation of mitochondrial activity [113] and
tumor progression [66–69,114]. Moreover, changes in subunit
composition of cytochrome c oxidase, observed in different
tissues or after hypoxic treatment, is associated to changes in the
activity of the complex itself [59,115]. Our results suggest an
unbalanced composition of the COX complex, with subunits
encoded by nuclear genes being affected more then those
encoded by mitochondrial DNA (Fig. 1), in keeping with
observation made in prostate, ovarian, colon, esophageal and
breast cancer, where an altered ratio between some nuclear-
encoded subunits (IV, Vb and VIc) to mitochondrial-encoded
subunits (I, II and III) has been proposed to alter the rate of
oxidative metabolism [66,116]. Evidence linking expression of
ATP-synthase subunits with the rate of oxidative metabolism,
has been reported in several tumor models [56,117–120].
RNA profiling assays also indicated down-regulation of
some key transcriptional regulators involved in the expression of
nuclear and mitochondrial respiratory genes and other proteins
involved in mitochondria functionality (see Fig. 8). Interest-
ingly, the down-regulation of the transcriptional coactivator
PGC-1α appears, that plays an essential role in mitochondrial
biogenesis, induction of genes of respiratory chain, fatty acid
oxidation, heme biosynthetic pathways, and that can be
stimulated by environmental signaling followed by variation
of cAMP levels in the cells [121–123]. Also interesting, the
down-regulation of UCP3 protein appears. In fact, while the
great number of studies carried out on this protein did not
completely clarify its function, several reports indicate that it is
involved in the enhancement of proton conductance when is
activated by ROS metabolism, and that this might be an impor-
tant way to attenuate mitochondrial ROS production and the
consequent oxidative damage [65,99,100]. Other authors
showed a correlation between levels of expression of UCP3
with fatty acid transport and oxidation in muscle [124–126], or
glucose metabolism in neuronal cells and UCP3 disrupted mice
[125–129].
By taking into account that a large number of reports
underline the importance of efficient oxidative phosphorylation,
and in particular the strong involvement of complexes IVand V,
in the execution of apoptosis [44,105,130–132], our data
converge to indicate a remodeling of energy metabolism and
partial uncoupling of mitochondria [10], as summarized in the
bottom panels in Fig. 8. Transformed cells do not increase
oxygen consumption in presence of uncoupler DNP, while
normal and reverted cells do. Transformed cells respond to
glucose shortage by substantially increasing ROS production
and apoptotic activity, while normal and reverted cells arrest in
G1. These responses are coherent with several findings reported
in the literature. For instance, deregulation of mitochondrialactivity induced by oncogenic K-ras should influence energetic
metabolism, as shown by inability to respond to DNP (ref. [10],
Fig. 8 bottom A) and to produce ATP in low glucose (Fig. 7D),
through increased ROS production [10] lead to apoptosis, in ras
transformed cells [91,133–135]. Such event is more evident in
cells grown in low initial glucose concentration (ref. [10], Fig. 8
bottom B and C).
Taken together, the transcriptional data presented in this
report indicate that deregulation of mitochondrial related genes
may contribute to the metabolic shift associated with K-Ras
transforming activity, also in consideration that reverted cells, in
which the GEF-DN is able to strongly decrease the level of Ras-
GTP [86,87], showed opposite regulation when compared to the
transformed cells, thereby supporting the notion that reported
responses are all linked to K-ras over-expression.
4.2. Dynamic alterations of mitochondrial mass and
morphology in transformed cells
Mitochondria are dynamic organelles that can change in
number and morphology during development, cell cycle, as
function of substrate availability and during the apoptotic
processes. In fact, at least under some conditions, mitochondria
in mammalian cells form a physically interconnected network
that may represent an efficient system for energy delivery,
calcium exchange, intermitochondrial DNA (mtDNA) comple-
mentation through exchange of genomes between mitochondria
(reviewed in [136]). This complex network is regulated by
processes of fusion and fission whose rate can be modulated by
growth conditions, ultimately bringing to an alteration in
mitochondrial number and size. Variations of mitochondrial
morphology have been shown to correlate with the switch from
oxidative phosphorylation to glycolysis and vice versa. A
decrease in mitochondrial connectivity leading to formation of
short, round mitochondria has also been associated with
conditions that compromise mitochondrial function [137,138].
Here we show that growing normal and transformed cells
exhibit different mitochondrial morphology. Microscopic
analysis of mitochondria in growing normal cells (24 h,
25 mM glucose) showed a less fragmented and organized
structure positioned around nucleus that became interconnected
and filamentous in cells arresting in G1 phase (96 h, 25 mM
glucose). These morphological changes are influenced by
glucose availability and cell cycle distribution (that is changing
during the time course of the experiment, ref. [10] and data not
shown). Mitochondria remodeling is tightly controlled by
multiple proteins involved in fusion and fission, while organelle
distribution is regulated through attachments to microtubules
and actin filaments [139–142]. Cell cycle-dependent changes in
mitochondria morphology have been previously reported [42]
and proposed to be strongly correlated to energy production in
relation to the cell cycle and to the metabolic status of the cells.
Fragmentation of mitochondrial mass and its localization in the
perinuclear region of the cells [42,143] has been associated with
the requirement of a metabolism focused on energy production,
protein and lipid synthesis for the next mitotic division. In
transformed cells mitochondria appeared as a less defined
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higher percentage of S phase cells at 96 h when compared to
normal cells. Fragmentation observed in transformed cells may
indicate also a less active mitochondria, often observed in
apoptotic cells or due to the switch to production of ATP by
glycolysis (ref. [10] and Fig. 8 bottom B and C). The parallel
analysis of mitochondrial mass and potential offers support to
the hypothesis that mitochondria of transformed cells are less
active. In fact normal and reverted cells, in presence of fer-
mentable substrate (25 mM glucose) together with a major
connection of mitochondrial network, showed an increase of
both mitochondrial mass and potential, while transformed cells
showed lower mitochondrial mass and potential in relation to
fragmented mitochondria. This difference is even more striking
by taking into account that a large fraction of transformed cells
remained unstained. Time-course-dependent strongly suggest
that ATP production in transformed cells is largely glucose-
dependent, since after 96 h of growth, all three cell lines have
used all glucose, but only transformed cells are unable to sustain
ATP production. Further, analysis of ATP content in cells grown
in 25 mM glucose and 50 μMCCCP for 24 h, showed reduction
of total ATP only in normal and revertant cell lines, confirming
that transformed cells rely on glycolysis more that on oxidative
phosphorylation (data not shown).
4.3. Final remarks
The results presented in this paper, together with the reported
partial uncoupling and larger fraction of apoptotic cells in the
transformed cell line [10], and the reversion of each of these
phenotypes by expression of the GEF-DN (ref. [10], Fig. 8),
indicate that activation of the Ras pathway strikingly impacts on
energy and signaling-related aspects of mitochondria function-
ality that in turn may affect the terminal phenotype of trans-
formed cells.
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